Braveheart Bio

The company's primary focus is developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions. HCM is one of the most common rare diseases, affecting approximately 1 in 500 people in the United States, and involves the thickening of the heart muscle, which impairs its ability to pump blood effectively. Braveheart Bio's business model centers on in-licensing and advancing promising drug candidates. The company's lead therapeutic, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from the Chinese pharmaceutical company Hengrui Pharma. This licensing deal for ex-China rights was valued at up to $1.1 billion. The business strategy is to develop BHB-1893 as a best-in-class molecule that offers improved efficacy, safety, and dosing convenience over existing treatments for HCM, such as Bristol Myers Squibb's Camzyos.

BHB-1893 is engineered to target myosin, a protein in heart cells responsible for contraction, which is overactive in HCM patients. By inhibiting this protein, the drug aims to improve the heart's performance. The candidate has undergone extensive clinical development, including a Phase 2 study in obstructive HCM (oHCM), an ongoing Phase 2 study in non-obstructive HCM (nHCM), and an ongoing Phase 3 trial in oHCM in China. Braveheart Bio plans to initiate global late-stage clinical development for BHB-1893 in 2026. Early data has shown that BHB-1893 can produce rapid and meaningful reductions in left ventricular outflow tract gradients in oHCM patients.